

Xtandi (enzalutamide), a case study

- Xtandi (enzalutamide) is a prostate cancer drug
- Costs \$30K in Canada and \$130K in the U.S.
- History
 - Developed at UCLA
 - 2005 - Licensed to Medivation
 - 2012 - Approved by FDA
 - 2016 - Rights purchased by Pfizer for \$14 billion
 - 2016 - Patent rejected by Indian patent office, paving way for generic manufacture
 - 2017 - Over activist opposition, UCLA files appeal of patent rejection
 - 2019 - UCLA wins appeal
- https://www.lamag.com/citythinkblog/ucla-xtandi-india/?fbclid=IwAR0u_3PhbddYniDynlwH-kZFKjn5QY6FbUBZtaRN_zE0kCkLW6ipRuC5hhc

